Evidence map›Paper›PMID 38335064›Full record

ArticleJAMA neurology2024

Time to Anticoagulation Reversal and Outcomes After Intracerebral Hemorrhage.

Kevin N Sheth, Nicole Solomon, Brooke Alhanti, Steven R Messe, Ying Xian, Deepak L Bhatt, J Claude Hemphill, Jennifer A Frontera, Raymond C Chang, Ilya M Danelich and 7 more

Open access · greenAbstract read
In one paragraph

Article in JAMA neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
27.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 75 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Observational
  9. Article
  10. Code Intracerebral Hemorrhage: A Quality Improvement Pilot Study.Mayo Clinic proceedings. Innovations, quality & outcomes · 2026
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 11 institutions in 2 countries.

Kevin N ShethYale Center for Brain and Mind Health, Yale University School of Medicine, New Haven, Connecticut.
Nicole SolomonDuke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina.
Brooke AlhantiDuke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina.
Steven R MesseDepartment of Neurology, University of Pennsylvania School of Medicine, Philadelphia.
Ying XianDepartment of Neurology, University of Texas at Southwestern, Dallas.
Deepak L BhattMount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, New York.
J Claude HemphillDepartment of Neurology, University of California, San Francisco.
Jennifer A FronteraDepartment of Neuology, New York University, New York.
Raymond C ChangAstraZeneca, Wilmington, Delaware.
Ilya M DanelichAstraZeneca, Wilmington, Delaware.
Joanna HuangAstraZeneca, Wilmington, Delaware.
Lee SchwammDepartment of Biomedical Informatics and Data Sciences, Yale School of Medicine, New Haven, Connecticut.
Eric E SmithDepartment of Clinical Neurosciences, Hotchkiss Brain Institute, University of Calgary, Alberta, Canada.
Joshua N GoldsteinDepartment of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School, Boston.
Brian Mac GroryDepartment of Neurology, Duke University School of Medicine, Durham, North Carolina.
Gregg C FonarowDivision of Cardiology, Ronald Reagan UCLA Medical Center, Los Angeles, California.
Jeffrey L SaverDepartment of Neurology, Ronald Reagan UCLA Medical Center, Los Angeles, California.
AstraZeneca (United States) · USDuke University · USRonald Reagan UCLA Medical Center · USYale University · USHarvard University · USMount Sinai Hospital · USNew York University · USThe University of Texas Southwestern Medical Center · USUniversity of Calgary · CAUniversity of California, San Francisco · USUniversity of Pennsylvania · US

Funding

Cardioembolism as a Mechanism of Central Retinal Artery OcclusionK23HL161426 · NHLBI · DUKE UNIVERSITY · PI Brian Mac Grory · 2022 to 2026
$951k
NHLBI NIH HHS K23 HL161426
6 · The paper itself

Abstract

Importance: Intracerebral hemorrhage (ICH) is the deadliest stroke subtype, and mortality rates are especially high in anticoagulation-associated ICH. Recently, specific anticoagulation reversal strategies have been developed, but it is not clear whether there is a time-dependent treatment effect for door-to-treatment (DTT) times in clinical practice. Objective: To evaluate whether DTT time is associated with outcome among patients with anticoagulation-associated ICH treated with reversal interventions. Design, Setting, and Participants: This cohort study used data from the American Heart Association Get With The Guidelines-Stroke quality improvement registry. Patients with ICH who presented within 24 hours of symptom onset across 465 US hospitals from 2015 to 2021 were included. Data were analyzed from January to September 2023. Exposures: Anticoagulation-associated ICH. Main Outcomes and Measures: DTT times and outcomes were analyzed using logistic regression modeling, adjusted for demographic, history, baseline, and hospital characteristics, with hospital-specific random intercepts to account for clustering by site. The primary outcome of interest was the composite inpatient mortality and discharge to hospice. Additional prespecified secondary outcomes, including functional outcome (discharge modified Rankin Scale score, ambulatory status, and discharge venue), were also examined. Results: Of 9492 patients with anticoagulation-associated ICH and documented reversal intervention status, 4232 (44.6%) were female, and the median (IQR) age was 77 (68-84) years. A total of 7469 (78.7%) received reversal therapy, including 4616 of 5429 (85.0%) taking warfarin and 2856 of 4069 (70.2%) taking a non-vitamin K antagonist oral anticoagulant. For the 5224 patients taking a reversal intervention with documented workflow times, the median (IQR) onset-to-treatment time was 232 (142-482) minutes and the median (IQR) DTT time was 82 (58-117) minutes, with a DTT time of 60 minutes or less in 1449 (27.7%). A DTT time of 60 minutes or less was associated with decreased mortality and discharge to hospice (adjusted odds ratio, 0.82; 95% CI, 0.69-0.99) but no difference in functional outcome (ie, a modified Rankin Scale score of 0 to 3; adjusted odds ratio, 0.91; 95% CI, 0.67-1.24). Factors associated with a DTT time of 60 minutes or less included White race, higher systolic blood pressure, and lower stroke severity. Conclusions and Relevance: In US hospitals participating in Get With The Guidelines-Stroke, earlier anticoagulation reversal was associated with improved survival for patients with ICH. These findings support intensive efforts to accelerate evaluation and treatment for patients with this devastating form of stroke.

Identifiers

PMID38335064
PMCPMC11002694
OpenAlexW4391693609

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.